Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), today announced that it will present for the first time pre-clinical data from its STimulator of INterferon Genes (STING) antagonist program at The Autoimmunity Conference organized by the Federation of American Societies for Experimental Biology (FASEB) in Pacific Grove, California, from July 7-12, 2019.
HOPKINTON, Mass., Jun. 27, 2019 –Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will present for the first time pre-clinical data from its STimulator of INterferon Genes (STING) antagonist program at The Autoimmunity Conference organized by the Federation of American Societies for Experimental Biology (FASEB) in Pacific Grove, California, from July 7-12, 2019.
“Aberrant activation of the STING pathway is believed to cause certain autoimmune and inflammatory diseases, including Systemic Lupus Erythematosus (SLE), Aicardi–Goutières Syndrome, Sjögren’s syndrome and certain other rare diseases,” commented Dr. Kris Iyer, co-founder and Chief Scientific Officer of Spring Bank Pharmaceuticals. “We are excited about the data from our STING antagonist program to be presented at The Autoimmunity Conference and the rapid progress of our novel STING antagonist program. Our STING antagonist compounds are designed to block aberrant STING-dependent signaling by a novel mechanism of action and are being developed to have therapeutic utility in certain autoimmune diseases, including various interferonopathies.”
Dr. Iyer continued, “The rapid advancement of our novel STING antagonist program is further demonstration of our capabilities at Spring Bank to develop a continuous pipeline of novel product candidates for diseases with significant unmet clinical needs. Our internally-developed product development pipeline, including inarigivir, a compound in Phase 2 trials for the treatment of chronic hepatitis B virus (HBV); SB 11285, an intravenously-administered STING agonist for the treatment of solid tumors; and our antisense oligonucleotide compound for HBV, is progressing in a manner that we anticipate multiple data readouts from these clinical and non-clinical development programs over the next six to eighteen months.”
Spring Bank’s poster presentation at The Autoimmunity Conference will show recent pre-clinical data from one of Spring Bank’s STING antagonist compounds, SB 36, including details on its novel mechanism of action and potent inhibition of interferon and pro-inflammatory cytokines in wild type and dysregulated cGAS-STING models. In vivo administration of SB 36 antagonized STING-agonist-induced interferon and cytokine production in the blood, spleen and liver in mice. These pre-clinical studies show that SB 36 has the potential for therapeutic applications in interferonopathies, as well as autoimmune and inflammatory diseases.
Details of the poster presentation are as follows:
Title: A Novel STING Antagonist for Interferonopathies and Autoimmune Diseases (Poster #36)
Dates: Monday, July 8, 2019 and Wednesday, July 10, 2019
Time: 7:30 p.m. to 10:00 p.m. Pacific Time
Location: Asilomar Conference Grounds, Pacific Grove, CA
Following the presentation, the poster will be available on the Publications page of the company’s website.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. The company’s lead product candidate, inarigivir, is being developed for the treatment of chronic hepatitis B virus (HBV). Inarigivir is designed to activate within hepatic cells retinoic acid-inducible gene 1 (RIG-I), which has been shown to inhibit HBV viral replication and induce the intracellular interferon signaling pathways for antiviral defense. The company is also developing its lead STING agonist product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers. For more information, please visitwww.springbankpharm.com.
Contacts
Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
(508) 473-5993
LifeSci Advisors, LLC
Ashley R. Robinson
(617) 535-7742
Source: Spring Bank Pharmaceuticals, Inc.
